Smoking cessation pharmacotherapy; varenicline or bupropion?
Bupropion
NRT
Smoking cessation
Varenicline
Journal
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
ISSN: 2008-2231
Titre abrégé: Daru
Pays: Switzerland
ID NLM: 101125969
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
30
07
2023
accepted:
31
08
2024
medline:
12
9
2024
pubmed:
12
9
2024
entrez:
12
9
2024
Statut:
aheadofprint
Résumé
Tobacco smoking is a worldwide health problem and one of the leading causes of premature deaths in last years. As there are lots of researches focusing on cessation strategies with attention to pharmacotherapy and behavioral counseling, the aim of this study was to compare two of the first-line FDA-approved pharmacotherapies for smoking cessation; varenicline and bupropion. This writing is an overview of researches published in Pubmed database from 2012 to 2022 with "Varenicline" and "Bupropion" as key words. Among the researches that were found, 24 articles were selected which mainly focused on comparison of these two medicines. Varenicline and bupropion are known as non-nicotinic pharmacotherapy and have been used in addition to nicotine replacement therapy for smoking cessation. Varenicline is partial agonist for α4β2 nicotinic acetyl choline receptors while bupropion, classified as an atypical antidepressant, is actually a norepinephrine and dopamine reuptake inhibitor. Although these treatments can result in some adverse effects including nausea, insomnia, anxiety, irritability, fatigue and abnormal dreams, their efficacy in reduction of craving and also maintenance of abstinence is well been studied and approved by FDA. Moreover, adverse effects are usually mild to moderate clinical symptoms which can be tolerated and also easily managed and prevented in cases. The efficacy and tolerability of varenicline and bupropion as treatments for smoking cessation is well understood. However, studies have shown that varenicline seems to be more effective in maintaining of abstinence and also reducing craving than bupropion and NRT.
Identifiants
pubmed: 39264407
doi: 10.1007/s40199-024-00539-6
pii: 10.1007/s40199-024-00539-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Tehran University of Medical Sciences.
Références
Yang M, Chen H, Johnson ML, Essien EJ, Peters RJ Jr, Wang X, et al. Comparative effectiveness of smoking cessation medications to attenuate weight gain following cessation. Subst Use Misuse. 2016;51(5):586–97. https://doi.org/10.3109/10826084.2015.1126744 .
doi: 10.3109/10826084.2015.1126744
pubmed: 27007975
Hays JT, Croghan IT, Baker CL, Cappelleri JC, Bushmakin AG. Changes in health-related quality of life with smoking cessation treatment. Eur J Public Health. 2012;22(2):224–9. https://doi.org/10.1093/eurpub/ckq137 .
doi: 10.1093/eurpub/ckq137
pubmed: 20884658
Jordan CJ, Xi ZX. Discovery and development of varenicline for smoking cessation. Expert Opin Drug Discov. 2018;13(7):671–83. https://doi.org/10.1080/17460441.2018.1458090 .
doi: 10.1080/17460441.2018.1458090
pubmed: 29587555
pmcid: 6179352
Ebbert J, Jimenez-Ruiz C, Dutro MP, Fisher M, Li J, Hays JT. Frequently Reported Adverse Events With Smoking Cessation Medications: Post Hoc Analysis of a Randomized Trial. Mayo Clin Proc. 2021;96(7):1801–11. doi: 10.1016/j.mayocp.2020.10.046.
doi: 10.1016/j.mayocp.2020.10.046
pubmed: 34112520
Jain R, Majumder P, Gupta T. Pharmacological intervention of nicotine dependence. Biomed Res Int. 2013;2013:278392. https://doi.org/10.1155/2013/278392 .
doi: 10.1155/2013/278392
pubmed: 24490153
pmcid: 3891736
Mahmoudi M, Coleman CI, Sobieraj DM. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. Int J Clin Pract. 2012;66(2):171–82. https://doi.org/10.1111/j.1742-1241.2011.02877.x .
doi: 10.1111/j.1742-1241.2011.02877.x
pubmed: 22257042
Scoville EA, Tindle HA, Wells QS, Peyton SC, Gurwara S, Pointer SO, et al. Precision nicotine metabolism-informed care for smoking cessation in Crohn’s disease: a pilot study. PLoS ONE. 2020;15(3): e0230656. https://doi.org/10.1371/journal.pone.0230656 .
doi: 10.1371/journal.pone.0230656
pubmed: 32214373
pmcid: 7098646
Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70(5):522–33. https://doi.org/10.1001/jamapsychiatry.2013.678 .
doi: 10.1001/jamapsychiatry.2013.678
pubmed: 23536105
pmcid: 4128024
Evins AE, Benowitz NL, West R, Russ C, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES Trial. J Clin Psychopharmacol. 2019;39(2):108–16. https://doi.org/10.1097/JCP.0000000000001015 .
doi: 10.1097/JCP.0000000000001015
pubmed: 30811371
pmcid: 6488024
Rose JE, Behm FM. Combination varenicline/bupropion treatment benefits highly dependent smokers in an adaptive smoking cessation paradigm. Nicotine Tob Res. 2017;19(8):999–1002. https://doi.org/10.1093/ntr/ntw283 .
doi: 10.1093/ntr/ntw283
pubmed: 29054128
King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology. 2012;37(3):641–50. https://doi.org/10.1038/npp.2011.232 .
doi: 10.1038/npp.2011.232
pubmed: 22048466
Cinciripini PM, Green CE, Robinson JD, Karam-Hage M, Engelmann JM, Minnix JA, et al. Benefits of varenicline vs. bupropion for smoking cessation: a bayesian analysis of the interaction of reward sensitivity and treatment. Psychopharmacology. 2017;234(11):1769–79. https://doi.org/10.1007/s00213-017-4580-2 .
doi: 10.1007/s00213-017-4580-2
pubmed: 28275830
pmcid: 5901731
Ashare RL, McKee SA. Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers. Exp Clin Psychopharmacol. 2012;20(1):63–70. https://doi.org/10.1037/a0025594 .
doi: 10.1037/a0025594
pubmed: 21942262
Little MA, Ebbert JO. The safety of treatments for tobacco use disorder. Expert Opin Drug Saf. 2016;15(3):333–41. https://doi.org/10.1517/14740338.2016.1131817 .
doi: 10.1517/14740338.2016.1131817
pubmed: 26715118
Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;2016(5):Cd006103. https://doi.org/10.1002/14651858.CD006103.pub7 .
doi: 10.1002/14651858.CD006103.pub7
pubmed: 27158893
pmcid: 6464943
Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. Treatment of tobacco smoking: a review. JAMA. 2022;327(6):566–77. https://doi.org/10.1001/jama.2022.0395 .
doi: 10.1001/jama.2022.0395
pubmed: 35133411
Abdul-Kader J, Airagnes G, D’Almeida S, Limosin F, Le Faou AL. [Interventions for smoking cessation in 2018]. Rev Pneumol Clin. 2018;74(3):160–9. https://doi.org/10.1016/j.pneumo.2018.03.004 .
doi: 10.1016/j.pneumo.2018.03.004
pubmed: 29650283
Brose LS, West R, Stapleton JA. Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice. Mayo Clin Proc. 2013;88(3):226–33. https://doi.org/10.1016/j.mayocp.2012.11.013 .
doi: 10.1016/j.mayocp.2012.11.013
pubmed: 23489449
Cinciripini PM, Kypriotakis G, Green C, Lawrence D, Anthenelli RM, Minnix J, et al. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: a randomized clinical trial. Depress Anxiety. 2022;39(5):429–40. https://doi.org/10.1002/da.23259 .
doi: 10.1002/da.23259
pubmed: 35535436
pmcid: 9705120
Nollen NL, Ahluwalia JS, Sanderson Cox L, Okuyemi K, Lawrence D, Samuels L, et al. Assessment of racial differences in pharmacotherapy efficacy for smoking cessation: secondary analysis of the EAGLES randomized clinical trial. JAMA Netw Open. 2021;4(1):e2032053. https://doi.org/10.1001/jamanetworkopen.2020.32053 .
doi: 10.1001/jamanetworkopen.2020.32053
pubmed: 33464316
pmcid: 7816102
Underner M, Perriot J, Peiffer G, Ruppert AM, de Chazeron I, Jaafari N. [Combinations of pharmacological treatments in smoking cessation. A systematic review]. Rev Mal Respir. 2021;38(7):706–20. https://doi.org/10.1016/j.rmr.2021.05.012 .
doi: 10.1016/j.rmr.2021.05.012
pubmed: 34215484
Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA. 2014;311(2):155–63. https://doi.org/10.1001/jama.2013.283185 .
doi: 10.1001/jama.2013.283185
pubmed: 24399554
pmcid: 3959999
Vogeler T, McClain C, Evoy KE. Combination bupropion SR and varenicline for smoking cessation: a systematic review. Am J Drug Alcohol Abuse. 2016;42(2):129–39. https://doi.org/10.3109/00952990.2015.1117480 .
doi: 10.3109/00952990.2015.1117480
pubmed: 26809272
Havard A, Choi SKY, Pearson SA, Chow CK, Tran DT, Filion KB. Comparison of cardiovascular safety for smoking cessation pharmacotherapies in a population-based cohort in Australia. JAMA Netw Open. 2021;4(11):e2136372. https://doi.org/10.1001/jamanetworkopen.2021.36372 .
doi: 10.1001/jamanetworkopen.2021.36372
pubmed: 34842922
pmcid: 8630569